JP2025510074A5 - - Google Patents
Info
- Publication number
- JP2025510074A5 JP2025510074A5 JP2024556319A JP2024556319A JP2025510074A5 JP 2025510074 A5 JP2025510074 A5 JP 2025510074A5 JP 2024556319 A JP2024556319 A JP 2024556319A JP 2024556319 A JP2024556319 A JP 2024556319A JP 2025510074 A5 JP2025510074 A5 JP 2025510074A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- tautomer
- salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2204142.0A GB202204142D0 (en) | 2022-03-24 | 2022-03-24 | Novel compounds |
| GB2204142.0 | 2022-03-24 | ||
| GBGB2213816.8A GB202213816D0 (en) | 2022-09-22 | 2022-09-22 | Novel compounds |
| GB2213816.8 | 2022-09-22 | ||
| GBGB2301448.3A GB202301448D0 (en) | 2023-02-01 | 2023-02-01 | Novel compounds |
| GB2301448.3 | 2023-02-01 | ||
| GB202301757 | 2023-02-08 | ||
| GB2301757.7 | 2023-02-08 | ||
| PCT/EP2023/057338 WO2023180388A1 (en) | 2022-03-24 | 2023-03-22 | 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510074A JP2025510074A (ja) | 2025-04-14 |
| JP2025510074A5 true JP2025510074A5 (enExample) | 2026-03-30 |
Family
ID=85937360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556319A Pending JP2025510074A (ja) | 2022-03-24 | 2023-03-22 | Ｐｒｏｔａｃにおけるデグロンとしての２，４－ジオキソテトラヒドロピリミジニル誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250205344A1 (enExample) |
| EP (1) | EP4499628A1 (enExample) |
| JP (1) | JP2025510074A (enExample) |
| CN (1) | CN119301111A (enExample) |
| CA (1) | CA3246569A1 (enExample) |
| WO (1) | WO2023180388A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260234157A1 (en) * | 2023-01-04 | 2026-08-13 | Gan & Lee Pharmaceuticals Co., Ltd. | Compound and method for targeted degradation of androgen receptor |
| US20240374588A1 (en) | 2023-04-07 | 2024-11-14 | Astrazeneca Ab | Irak4 protacs |
| CN122161821A (zh) * | 2023-07-12 | 2026-06-05 | 上海壹迪生物技术有限公司 | 氰基喹啉类靶向蛋白降解分子、其制备方法和应用 |
| IL326555A (en) | 2023-09-22 | 2026-04-01 | Glaxosmithkline Ip Dev Ltd | Androgen receptor protacs |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025108404A1 (zh) * | 2023-11-22 | 2025-05-30 | 广东东阳光药业股份有限公司 | 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途 |
| US20250197411A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
| WO2025162210A1 (zh) | 2024-02-04 | 2025-08-07 | 上海超阳药业有限公司 | 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途 |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| TW202617722A (zh) * | 2024-06-19 | 2026-05-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮雜環類衍生物抑制劑、其製備方法和應用 |
| WO2026120044A1 (en) * | 2024-12-04 | 2026-06-11 | Astrazeneca Ab | Smarca2 degraders and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| IL319363A (en) * | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2020118098A1 (en) * | 2018-12-05 | 2020-06-11 | Vividion Therapeutics, Inc. | Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment |
| WO2020160295A1 (en) | 2019-01-30 | 2020-08-06 | Montelino Therapeutics, Llc | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| JP2022521825A (ja) | 2019-03-28 | 2022-04-12 | エッサ ファーマ，インコーポレイテッド | アンドロゲン受容体モジュレーター及びタンパク質分解誘導キメラリガンドとして使用するための方法 |
| US12331061B2 (en) | 2019-04-18 | 2025-06-17 | Accutar Biotechnology Inc. | Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof |
| BR112021020775A2 (pt) | 2019-04-18 | 2021-12-14 | Hinova Pharmaceuticals Inc | Classe de compostos heterocíclicos quiméricos bifuncionais para a degradação direcionada de receptores de andrógeno e uso dos mesmos |
| MX2022004526A (es) | 2019-10-17 | 2022-07-21 | Arvinas Operations Inc | Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6. |
| PE20230782A1 (es) | 2020-09-30 | 2023-05-09 | Astrazeneca Ab | Compuestos y su uso en el tratamiento del cancer |
-
2023
- 2023-03-22 CN CN202380029742.4A patent/CN119301111A/zh active Pending
- 2023-03-22 CA CA3246569A patent/CA3246569A1/en active Pending
- 2023-03-22 WO PCT/EP2023/057338 patent/WO2023180388A1/en not_active Ceased
- 2023-03-22 JP JP2024556319A patent/JP2025510074A/ja active Pending
- 2023-03-22 US US18/849,815 patent/US20250205344A1/en active Pending
- 2023-03-22 EP EP23715429.9A patent/EP4499628A1/en active Pending